Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

General Counsel

Chief Business Officer

SVP, Finance and Accounting

SVP, Chief Scientific Officer

Chief Medical Officer

Chief Financial Officer

EVP, Chief Development Officer

President and CEO

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; CX-2051, a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801, a dually masked, conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, Astellas Pharma Inc., ModernaTX, Inc., and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in South San Francisco, California.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-26	Premium	acquired	Premium	Premium	Premium	CEO
2024-03-19	Premium	sold	Premium	Premium	Premium	General Counsel
2024-03-19	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2024-03-19	Premium	sold	Premium	Premium	Premium	SVP, Finance and Accounting
2024-03-19	Premium	sold	Premium	Premium	Premium	CEO
2024-03-19	Premium	sold	Premium	Premium	Premium	SVP, Chief Scientific Officer
2024-01-18	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-01-18	Premium	acquired	Premium	Premium	Premium	General Counsel
2024-01-18	Premium	acquired	Premium	Premium	Premium	CEO
2024-01-18	Premium	acquired	Premium	Premium	Premium	SVP, Chief Scientific Officer
2024-01-18	Premium	acquired	Premium	Premium	Premium	SVP, Finance and Accounting
2024-01-18	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2023-12-20	Premium	sold	Premium	Premium	Premium	SVP, Chief Scientific Officer
2023-12-20	Premium	sold	Premium	Premium	Premium	SVP, Finance and Accounting
2023-12-20	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2023-12-20	Premium	sold	Premium	Premium	Premium	General Counsel
2023-12-20	Premium	sold	Premium	Premium	Premium	CEO
2023-12-17	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2023-12-17	Premium	acquired	Premium	Premium	Premium	SVP, Chief Scientific Officer
2023-12-17	Premium	acquired	Premium	Premium	Premium	SVP, Finance and Accounting
2023-12-17	Premium	acquired	Premium	Premium	Premium	General Counsel
2023-12-17	Premium	acquired	Premium	Premium	Premium	CEO
2023-09-22	Premium	sold	Premium	Premium	Premium	SVP, Chief Scientific Officer
2023-09-22	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2023-09-22	Premium	sold	Premium	Premium	Premium	CEO

CTMX - CytomX Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for CTMX